Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
An international team of scientists have revealed the genetic root of prostate cancers in individual men, demonstrating that tumors share common gene faults which could potentially offer new targets for treatment. Prostate cancer is the second most common cancer and second leading cause of cancer death in men.
The research, published in Nature, is part of the International Cancer Genome Consortium - a global project committed to revealing genetic changes driving prostate cancer using the most up-to-date gene-sequencing technology available.
Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer (CSI-TC) who underwent orchiectomy, according to a pair of studies published in the December and January issues of the Journal of Clinical Oncology.
“Most patients with CSI-TC are cured by orchiectomy alone,” wrote study authors led by Christian Kollmannsberger, MD, of the University of British Columbia in Vancouver. “With highly effective chemotherapy providing a safety net, ultimate cure rates approach 100% irrespective of the postorchiectomy strategy employed.” Thus, diminishing morbidities associated with treatment is a primary concern.
Among older men with high-risk prostate cancer, receiving androgen-deprivation therapy in combination with radiotherapy reduced cause-specific and all-cause mortality by as much as 50% when compared with those who received androgen-deprivation therapy alone, results from a large-scale data review showed.
In fact, men over the age of 65 with locally advanced prostate cancer risk significantly higher mortality rates if they are treated with androgen-deprivation therapy (ADT) without accompanying radiotherapy (RT), according to the authors of a study published online Jan. 5 in the Journal of Clinical Oncology.
Among men with prostate cancer, those who lead active lifestyles have better survival rates than those who don’t, a new study suggests.
There are many benefits to being physically active, but the new results suggest there are “specific effects also on the survival among prostate cancer patients,” said the study's lead author Stephanie Bonn of the Karolinska Institute in Stockholm.
Robot-assisted radical prostatectomy (RARP) confers excellent long-term control of prostate cancer (PCa), according to a study of what researchers believe is the largest series to date to look at oncologic outcomes after RARP.
For patients with bladder cancer, smoking status and primary source of information correlate with awareness of the harms of tobacco use, according to a study published in Cancer.
Clinical prognostic groupings for localised prostate cancers are imprecise, with 30—50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors.
Holidays are traditionally viewed as a time to celebrate. Many people enjoy reuniting with family and friends, giving and receiving gifts, and celebrating religious traditions during this time. However, sometimes people with cancer and their loved ones feel "out of step" from the rest of the world during the holidays.
Kegel exercises to strengthen pelvic floor muscles, bladder training and weight loss and exercise are effective nonsurgical treatment options for women with urinary incontinence (UI), this according to a new evidence-based clinical practice guideline from the American College of Physicians.
The American Society of Clinical Oncology (ASCO) has endorsed guidelines from the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) on the use of adjuvant and salvage radiotherapy after prostatectomy, with a few caveats.
An ASCO guideline endorsement panel determined that the guideline recommendations, which were published last year, are clear and thorough, and are based on the most relevant scientific evidence.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.